How to buy Kamada stock

Kamada Ltd is a drug manufacturers-specialty & generic business based in the US. Kamada shares (KMDA) are listed on the NASDAQ and all prices are listed in US Dollars. Kamada employs 408 staff and has a trailing 12-month revenue of around 0.00.

Kamada share price

Use our graph to track the performance of KMDA stocks over time.

Kamada shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$5.78 - $13.33
50-day moving average	$6.16
200-day moving average	$6.71
Wall St. target price	$11.00
PE ratio	16
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.38

Buy Kamada shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Kamada stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Kamada Ltd by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Kamada under- or over-valued?

Valuing Kamada stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Kamada's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Kamada's P/E ratio

Kamada's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Kamada shares trade at around 16x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Kamada's PEG ratio

Kamada's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 8.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Kamada's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Kamada's EBITDA

Kamada's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $23.1 million.

The EBITDA is a measure of a Kamada's overall financial performance and is widely used to measure a its profitability.

Kamada financials

Revenue TTM	$133.2 million
Operating margin TTM	14.44%
Gross profit TTM	$47.6 million
Return on assets TTM	6.26%
Return on equity TTM	10.92%
Profit margin	12.86%
Book value	$3.99
Market capitalisation	$272.9 million

TTM: trailing 12 months

Shorting Kamada shares

There are currently 999,263 Kamada shares held short by investors – that's known as Kamada's "short interest". This figure is 3.1% up from 968,912 last month.

There are a few different ways that this level of interest in shorting Kamada shares can be evaluated.

Kamada's "short interest ratio" (SIR)

Kamada's "short interest ratio" (SIR) is the quantity of Kamada shares currently shorted divided by the average quantity of Kamada shares traded daily (recently around 77462.248062015). Kamada's SIR currently stands at 12.9. In other words for every 100,000 Kamada shares traded daily on the market, roughly 12900 shares are currently held short.

However Kamada's short interest can also be evaluated against the total number of Kamada shares, or, against the total number of tradable Kamada shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kamada's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Kamada shares in existence, roughly 20 shares are currently held short) or 0.0344% of the tradable shares (for every 100,000 tradable Kamada shares, roughly 34 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kamada.

Find out more about how you can short Kamada stock.

Kamada share dividends

We're not expecting Kamada to pay a dividend over the next 12 months.

Kamada share price volatility

Over the last 12 months, Kamada's shares have ranged in value from as little as $5.78 up to $13.33. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kamada's is 0.3454. This would suggest that Kamada's shares are less volatile than average (for this exchange).

Kamada overview

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; AeroBika, an OPEP device; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine.

Frequently asked questions

• What percentage of Kamada is owned by insiders or institutions?

  Currently 16.602% of Kamada shares are held by insiders and 40.268% by institutions.

• How many people work for Kamada?

  Latest data suggests 408 work at Kamada.

• When does the fiscal year end for Kamada?

  Kamada's fiscal year ends in December.

• Where is Kamada based?

  Kamada's address is: 2 Holzman Street, Rehovot, Israel, 7670402

• What is Kamada's ISIN number?

  Kamada's international securities identification number is: IL0010941198

• What is Kamada's CUSIP number?

  Kamada's Committee on Uniform Securities Identification Procedures number is: M6240T109